Teriparatide 743963 226092071 2008-07-16T20:04:21Z Edgar181 491706 image, CAS {{drugbox | IUPAC_name = | image = Teriparatide.png | CAS_number = 52232-67-4 | ATC_prefix = H05 | ATC_suffix = AA02 | PubChem = 16133850 | DrugBank = | chemical_formula = | C=181|H=291|N=55|O=51|S=2 | molecular_weight = 4117.72 g/mol | bioavailability = 95% | protein_bound = | metabolism = Hepatic (nonspecific proteolysis) | elimination_half-life = SubQ: 1 hour | excretion = Renal (metabolites) | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_US = <!-- A / B / C / D / X --> | pregnancy_category= C | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> | legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | legal_status = | routes_of_administration = SubQ }} '''Teriparatide''' ('''Forteo''') is a [[recombinant]] form of [[parathyroid hormone]], used in the treatment of advanced [[osteoporosis]]. It is manufactured and marketed by [[Eli Lilly and Company]]. ==Administration== Teriparatide is administered by injection once a day in the thigh or abdomen. The recommended dose is 20 μg per day. ==Uses== Teriparatide has an ongoing clinical trial to evaluate its effectiveness in treating the symptoms of [[osteogenesis imperfecta]].<ref>[http://www.clinicaltrials.gov/ct/show/NCT00131469 Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta - Full Text View - ClinicalTrials.gov<!-- Bot generated title -->]</ref> Teriparatide should not be prescribed for patients who are at increased risks for osteosarcoma. This includes those with [[Paget's Disease]] of bone or unexplained elevations of serum alkaline phosphate, open [[epiphysis]], or prior radiation therapy involving the skeleton. ==Mechanism of action== Teriparatide is the portion of human [[parathyroid hormone]] (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density. Teriparatide is the first FDA approved agent for the treatment of osteoporosis that stimulates new bone formation. ==FDA approval== Teriparatide was approved by the [[Food and Drug Administration]] (FDA) on [[26 November]], [[2002]], for the treatment of [[osteoporosis]] in men and [[postmenopausal]] women who are at high risk for having a fracture. The drug is also approved to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. === References === {{reflist}} === External links === *[http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202547.html Teriparatide at National Institutes for Health]. {{Calcium homeostasis}} [[Category:Drugs]] [[Category:Eli Lilly and Company]]